Drug Database
CS

CSF-GM (Leucogen)

✓ Approved

LG Chem Ltd. · CSF2RA · Recombinant Proteins

What is CSF-GM?

CSF-GM is a recombinant proteins developed by LG Chem Ltd.. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesLeucogen
CompanyLG Chem Ltd.
Drug ClassRecombinant Proteins
Molecular TargetCSF2RA
RouteInjectable (Others)
StatusApproved

Mechanism of Action

Molecular Targets

CSF-GM acts on 1 molecular target:

CSF2RAcolony stimulating factor 2 receptor subunit alpha (CD116, CSF2RX)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

CSF-GM is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Leukaemia✓ Approved
Blood and lymphatic system disordersMyelosuppression✓ Approved

Related Research Articles

PubMedFrontiers in nutrition2026-08-25

Dietary index for gut microbiota and odds of gestational diabetes mellitus: associations with inflammatory and metabolic biomarkers.

Su Yi Y, Du Xiuping X, Song Zhiying Z, He Xifeng X

Gestational diabetes mellitus (GDM) is a common metabolic disorder of pregnancy associated with adverse maternal and neonatal outcomes. Emerging evidence suggests that dietary patterns supportive of gut microbial health and associated systemic inflammation may contribute to the pathophysiology of GDM. This study evaluated the association between a dietary index oriented toward gut microbiota (DI-GM)-comprising foods previously linked to beneficial gut microbial composition-and GDM odds, metabolic profiles, inflammatory markers, and pregnancy outcomes. This case-control study included 800 pregnant women (400 GDM cases and 400 controls) at 24-28 weeks of gestation. Dietary intake was assessed using a validated food frequency questionnaire, and DI-GM scores were derived based on intake of microbiota-supportive and disruptive foods. Biochemical measurements included glucose parameters, lipid profile, hs-CRP, IL-6, TNF-α, and lipopolysaccharide. Multivariable logistic regression and structural equation modeling were used for association and mediation analyses. Women with GDM had lower DI-GM scores than controls (7.09 ± 1.64 vs. 9.52 ± 1.83, p < 0.001). In the fully adjusted model (Model 2), women in the highest DI-GM tertile (T3) had 55.4% lower odds of GDM compared with those in the lowest tertile (T1) (OR = 0.446). A significant inverse trend was observed across DI-GM tertiles (P trend = 0.002), indicating a dose-response relationship. Each 1-unit increase in DI-GM score was associated with an 11.0% lower adjusted odds of GDM (OR = 0.890); however, the association appeared to be nonlinear, with the strongest protective effect observed in the highest tertile. These findings suggest a potential threshold effect, whereby clinically meaningful benefits become evident primarily at higher levels of dietary adherence. The highest DI-GM tertile demonstrated lower fasting glucose, HbA1c, HOMA-IR, triglycerides, hs-CRP, and LPS, alongside higher HDL-C (all p < 0.05). Among women with GDM, higher DI-GM scores were strongly associated with lower rates of cesarean delivery, preeclampsia, gestational hypertension, macrosomia, neonatal hypoglycemia, NICU admission, and respiratory distress syndrome (all P-trend < 0.001). However, in the control group, this protective trend was not observed for any outcome except for a paradoxical significant increase in cesarean delivery with higher DI-GM adherence (P-trend < 0.001), while all other outcomes showed no significant trends (p > 0.10). Exploratory mediation analyses suggested hs-CRP may partially explain the DI-GM-glycemic association, but concurrent measurement precludes causal mediation. The negative indirect effects indicate an inconsistent mediation pattern, suggesting hs-CRP may not function as a classical mediator but rather reflects shared metabolic pathways or residual confounding. These findings are exploratory and hypothesis-generating, not confirmatory. Greater adherence to a microbiota-oriented dietary pattern was associated with lower GDM odds and improved maternal-neonatal outcomes. However, without direct gut microbiota measurement, these findings represent associations-not confirmation-of diet-microbiota-inflammation pathways, and require further investigation.

PubMedIndian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine2026-08-25

Chandipura Virus: "The Silent Threat Emerging in India's Viral Landscape".

Bindu D D, Jacob Saramma M SM

Chandipura virus (CHPV) has reemerged as a serious human pathogen related with acute encephalitis outbreaks. CHPV infection has been detected in various parts of Western, Central, and South India. In India, from June to August 2024, there were 245 reported cases of acute encephalitis syndrome (AES) with 82 deaths and 64 confirmed cases of CHPV; being the largest outbreak in the recent times. Phlebotomus and Sergentomyia species of sandflies have been identified as potential vectors. The virus has been detected in the whole blood and/or CSF of patients using reverse-transcriptase polymerase chain reaction, apart from detecting IgM and IgG by ELISA. No specific treatment is available and management relies on symptomatic care and vector control. Surveillance of AES cases across 36 States/UTs is implemented through Integrated Disease Surveillance Program of the Government of India. Awareness programs on the management of CHPV should be conducted for healthcare workers, especially where the disease has been endemic. Education programs on CHPV should be streamed in the media and rural areas. Vector control is essential to prevent the infection. Hence, a collaborative, "One Health approach" is necessary for prevention and control. Moreover, research efforts are focused on developing diagnostics, vaccines, and antivirals, with two potential vaccines awaiting clinical trials.

PubMedCureus2026-08-25

A Recurrent and Atypical Form of Guillain-Barré Syndrome: A Case Report.

Ed Dafali Larbi L, Semlali Shaimae S, Lachraf Hind H, Elharrak Saad S et al.

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy characterized by rapidly progressive sensorimotor impairment that is classically ascending and monophasic. Recurrent and descending forms are rare and may complicate diagnosis. We report an atypical recurrent case of GBS in a child presenting with descending paralysis. We describe a nine-year-old girl with a history of typical GBS who was admitted to the pediatric ICU for acute descending flaccid paralysis. The clinical course rapidly progressed to tetraplegia with bulbar and respiratory involvement. Electroneuromyography showed acute demyelinating motor polyneuropathy, CSF analysis revealed albuminocytologic dissociation, spinal MRI demonstrated cauda equina nerve root enhancement, and anti-ganglioside antibodies were positive. The patient required mechanical ventilation and multiple courses of IVIG, with subsequent significant neurological recovery and complete remission at three months. Recurrent GBS is rare. Descending paralysis is atypical in this disease and may delay diagnosis. In such cases, repeated clinical evaluation and supportive paraclinical investigations are essential. The benefit of repeated courses of IVIG in poorly responsive cases remains uncertain and is supported by limited evidence. This case highlights the importance of considering GBS in acute flaccid paralysis, even in atypical and recurrent presentations, and underscores the diagnostic value of paraclinical investigations in such contexts.

PubMedCase reports in medicine2026-08-25

Undiagnosed Pheochromocytoma During Pregnancy Presenting Initially With Neurological Manifestations: A Case Report.

Babaei Tahereh T, Hosseini Seyed Ahmad SA, Majidi Hadi H, Sheidaei Somayeh S et al.

A 50-year-old pregnant woman (G3Ab2) who had her fourth IVF procedure during the first trimester of her pregnancy is described in this article as having a rare incidence of acute paraplegia. The patient's early symptoms included headache, sudden lower limb weakness, urine retention, back discomfort, and uncontrolled hypertension. The patient had a history of infertility, thyroidectomy, hypertension, and repeated spontaneous abortions. After transverse myelitis was confirmed by spinal MRI, methylprednisolone pulse therapy and plasmapheresis were started as treatments. Subsequent analysis of CSF fluid showed purulent meningitis. An unexpected abortion occurred 48 h later. She had fast hypotension, confusion, and a hemoglobin drop from 10 to 5 g/dL over 72 h. A tumor in the left adrenal gland and a sizable, active hematoma in the right adrenal gland were discovered by abdominal imaging. After a right adrenalectomy and mass draining were done in an emergency, the pheochromocytoma was finally diagnosed. The patient was briefly stabilized postsurgery but ultimately succumbed. This case is one of the limited instances documented in the scientific literature, when the emergence of neurological symptoms from transverse myelitis serves as the initial manifestation of pheochromocytoma, in conjunction with high-risk pregnancy, IVF, and an aggressive clinical trajectory. Consequently, in instances of unstable or early hypertension in pregnancy with neurological symptoms, differential diagnosis should include neuroendocrine tumors such as pheochromocytoma.

PubMedAnesthesiology research and practice2026-08-25

Incidence, Onset Time and Predictors of Postdural Puncture Headache Among Mothers Who Underwent Caesarean Section in Hospitals, Ethiopia: A Prospective Cohort Study.

Tesfahun Esubalew E, Takele Eden E, Andargie Dereje D, Hailemeskel Solomon S

Postdural puncture headache (PDPH) is a significant complication of spinal anaesthesia, especially in obstetric patients. It is triggered by the leakage of cerebrospinal fluid (CSF) through the puncture in the Dura mater. Understanding the timing of PDPH onset is crucial for early diagnosis and treatment, but previous studies have not fully explored its timing and associated factors. To determine the incidence and predictors of PDPH in women who deliver by caesarean section under spinal anaesthesia. A prospective follow-up study was conducted from March 7 to May 8, 2025, among 365 mothers who underwent caesarean section under spinal anaesthesia at government hospitals found in Debre Berhan, Ethiopia. Data were collected using a structured interviewer-administered questionnaire. The Kaplan-Meier method was used to estimate the survival time for PDPH, with the log-rank test for curve comparison. Cox regression analysis was conducted to identify predictor variables. The cumulative incidence of PDPH was 33.7% (95% CI: 28.9%, 38.7%), and incidence density was 3.75 (95% CI: 3.11, 4.47) per 1000 person-hours of observation. The mean time to onset of PDPH was 28.9 h (approximately 1.4 days). The restricted mean survival time was 28.98 Hr (95% CI: 25.78, 32.17). Multiple attempts during the procedure AHR 1.69 (95% CI: 1.104, 2.606; p < 0.01), larger needle size AHR 8.22 (95% CI: 4.94, 13.67; p < 0.001) and anaesthetist having less than 3 years of experience AHR 2.7 (95% CI 1.62, 4.51; p < 0.001) were found to be predictors of PDPH. This study confirmed that reducing the magnitude of PDPH requires limiting the number of puncture attempts and usage of Quincke spinal needles (22G) or fine-gauge needles (24G-26G).

PubMedImmunopharmacology and immunotoxicology2026-08-24

Protective effects of histamine H4 receptor antagonist on the inflammatory responses in B cells in a mouse model of multiple sclerosis.

Al-Mazroua Haneen A HA, Alhamami Hussain N HN, Nadeem Ahmed A, Ansari Mushtaq A MA et al.

Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS) driven by autoimmune mechanisms. However, growing evidence indicates that B lymphocytes may contribute to the disease through antigen presentation and the production of proinflammatory mediators. This study aimed to examine the effect of JNJ 10191584 (JNJ), a potent and selective H4R antagonist, on the progression of EAE and to uncover the underlying mechanisms. The research explored the potential impact of H4R antagonists on inflammatory responses in B cells within an EAE mouse model of MS. EAE mice received an oral dose of JNJ at 6 mg/kg daily, starting on day 10 and continuing until day 42. Flow cytometry assessed JNJ's effect on the expression of NF-κB p65, IκBα, Notch1, Notch3, IL-2, IL-6, GM-CSF, iNOS, TNF-α, and MCP-1 in CD19+ B cells. RT-PCR was used to evaluate the impact of JNJ on mRNA levels of these inflammatory markers in brain tissue. In EAE mice, JNJ treatment reduced the number of CD19+ cells expressing NF-κB p65, IκBα, Notch1, Notch3, IL-2, IL-6, GM-CSF, iNOS, and MCP-1. Additionally, JNJ decreased mRNA expression of inflammatory markers in brain tissue compared with vehicle-treated mice. These results suggest that targeting H4R with antagonists could offer a new therapeutic approach for MS by specifically modulating B-cell-mediated inflammation.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about CSF-GM